
Sign up to save your podcasts
Or


In this interview, Andrew M. Kates, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top General CardiologyTakeaways from 2024. Dr. Kates discusses the 2024 Perioperative Guidelines, cardiac rehab, ACC's proposal for a new Board of Cardiovascular Medicine, and more.
Bhave NM, Cibotti-Sun M, Moore MM. 2024 perioperative cardiovascular management for noncardiac surgery guideline-at-a-glance. J Am Coll Cardiol 2024;84:1970-75.
Pack OR, Keys T, Priya A, et al. Is 70% achievable? Hospital-level variation in rates of cardiac rehabilitation use among medicare beneficiaries. JACC Adv 2024;3:101275.
FDA Update: Acoramidis Approved to Reduce CV Death, Hospitalization in Patients With ATTR-CM (ACC.org). 2024. Available at https://www.acc.org/Latest-in-Cardiology/Articles/2024/11/26/15/02/fda-update-acoramidis-approved-to-reduce-cv-death-hospitalization-in-patients-with-attr-cm. Accessed 12/10/24.
Gillmore JD, Judge DP, Cappelli F, et al., on behalf of the ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132-42.
Board of Cardiovascular Medicine (ACC.org). 2024. https://cvboard.org/. Accessed 12/10/24.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
By American College of Cardiology3.8
5858 ratings
In this interview, Andrew M. Kates, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top General CardiologyTakeaways from 2024. Dr. Kates discusses the 2024 Perioperative Guidelines, cardiac rehab, ACC's proposal for a new Board of Cardiovascular Medicine, and more.
Bhave NM, Cibotti-Sun M, Moore MM. 2024 perioperative cardiovascular management for noncardiac surgery guideline-at-a-glance. J Am Coll Cardiol 2024;84:1970-75.
Pack OR, Keys T, Priya A, et al. Is 70% achievable? Hospital-level variation in rates of cardiac rehabilitation use among medicare beneficiaries. JACC Adv 2024;3:101275.
FDA Update: Acoramidis Approved to Reduce CV Death, Hospitalization in Patients With ATTR-CM (ACC.org). 2024. Available at https://www.acc.org/Latest-in-Cardiology/Articles/2024/11/26/15/02/fda-update-acoramidis-approved-to-reduce-cv-death-hospitalization-in-patients-with-attr-cm. Accessed 12/10/24.
Gillmore JD, Judge DP, Cappelli F, et al., on behalf of the ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132-42.
Board of Cardiovascular Medicine (ACC.org). 2024. https://cvboard.org/. Accessed 12/10/24.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

523 Listeners

317 Listeners

498 Listeners

169 Listeners

883 Listeners

19 Listeners

31 Listeners

298 Listeners

3,348 Listeners

136 Listeners

1,148 Listeners

39 Listeners

367 Listeners

426 Listeners

36 Listeners